The potential to predict TKI activity based on ctDNA analysis was demonstrated since the detection of KIT mutations in plasma appeared to correlate with outcomes in patients with metastatic TKI‐resistant GIST treated with third‐ and fourth‐line TKI treatment. Here, KIT is linked to gastrointestinal stromal tumor.